PIK3CA and aneurysmal bone cyst: The phase 3 IPATunity130 trial included two independent randomized cohorts (Cohort A in TNBC and Cohort B in HR+ HER2-negative [HER2–] unresectable locally advanced or metastatic breast cancer [aBC]) evaluating ipatasertib plus paclitaxel combination therapy and a third single-arm signal-seeking cohort in patients with TNBC whose tumors did not have PIK3CA/AKT1/PTEN alterations (Cohort C) evaluating a triplet combination of ipatasertib, paclitaxel and atezolizumab.